A Clinical Trial Comparing TQC3927 Inhaled Powder With Glycopyrronium Bromide and Formoterol Inhaled Aerosol (Biovoping® Lingchang®) for the Treatment of Chronic Obstructive Pulmonary Disease

Stopped The sponsor has decided to suspend study progress. Further implementation of the study is pending notification.

Conditions

• Chronic Obstructive Pulmonary Disease

Interventions

• DRUG: TQC3927 inhalation aerosol
• DRUG: Glyceryl bromide/formoterol inhalation aerosol

Sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.